XLR Medical Corp.

• Public
• US

Dow Jones Description

We were incorporated on February 2, 2001 under the laws of the State of Nevada. Until September 13, 2004, our business was focused on the acquisition, exploration and development of mineral properties. Following a review of our business, our Board of Directors determined that it was in the Companys best interests to discontinue our mineral exploration business and to change the focus of our operations to the pursuit of opportunities in the biotechnology field. Effective on September 13, 2004, we abandoned our mineral exploration business to focus on the business opportunities presented by our acquisition of TSI Medical Corp. (TSI) and by the unique cancer treatment technology currently being developed by Exelar Medical Corporation (EMC). EMC is a joint venture company established by TSI and the Exelar Corporation (Exelar), the original developers of the technology. Our acquisition of and merger with TSI has been accounted for as a reverse acquisition. As such, TSI has been treated as the acquiring entity for accounting and financial reporting purposes. As such, the fiscal year end of TSI, being January 31, 2004, has been adopted for purposes of our reporting obligations under the Securities Act of 1933, as amended (the Securities Act) and the Securities Exchange Act of 1934, as amended (the Exchange Act), commencing on September 15, 2004.

Chairman of the BoardDouglas P Boyd

Contact Information

Peer Companies

• Berkshire Hathaway Inc.
• Avaya Inc.
• Aviva Plc.
• Marsh & McLennan Companies Inc.
• Lincoln National Corp.

NAICS Code Miscellaneous Intermediation: 523910